These results indicate that high peptide dose vaccine favors the early selection (after 4v) of tumor antigen-specific CD8 T-cells expressing TCRs with increased binding avidity (i.e., slower off-rates) compared to low peptide/CpG or high CpG dose. Here, CD8A is linked to neoplasm.